Is MDxHealth S.A. (MDXH) a Buy, Sell, or Hold?
NASDAQ : MDXH
MDxHealth S.A.
$0.418 USD
$0.01 (1.95%)
- Volume
- 147.7K
- Average Volume
- 840.79K
- Market Capitalization
- $21.47M
- P/E Ratio
- -0.62
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $5.33
- Year Low
- $0.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.08
Company Overview
NASDAQ
Michael K. McGarrity
Medical - Diagnostics & Research
Healthcare
MDXH
364
BE
USD
Liquidity Metrics
-7.86
1.08
0.94
0.59
0.00
Sales & Valuation
$107.88M
0.26
-1.73
-13.12
-0.03
Profitability
-$0.67
-$33.52M
-32.17%
-33.95%
402.97%
-17.67%
P/E Metrics
-0.62
-0.01
-0.01
Analyst Price Target & Rating
$4.00
$4.00
$4.00
2/5
6 Analysts
-89.55%
Financial Health Scores
-3.35
2/9
$3.88M
$147.95M
$160.05M
-$36.07M
Key Metrics (TTM)
$87.14M
1.07
-14.60
1.08
402.97%
-12.74%
-127.47%
-7.77%
28 days
Company Executives
| Name | Title |
|---|---|
| Kim Leroux | Executive Vice President of Revenue Cycle Management |
| Scott McMahan | Vice President of Finance and Accounting |
| Joseph Sollee | Executive Vice President of Corporate Development & General Counsel |
| Michael K. McGarrity | Chief Executive Officer & Executive Director |
| Ron Kalfus | Interim Chief Financial Officer |
| John A. Bellano | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About MDxHealth S.A. (NASDAQ:MDXH) Stock
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHe ... alth SA in October 2010.
2026-07-24 16:59:00
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency IRVINE, California – July 24, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leader in urology-focused precision diagnostics, today announced that the Company received an additional notification letter (the “Additional Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) related to the recent reduction in the price for the Company's ordinary shares. The initial notice, reported by the Company in its Form 6-K filed on July 2, 2026, related to the Company's non-compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing.
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
2026-07-02 16:00:00
IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.
2026-06-29 08:00:00
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world's leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.
MDxHealth Q1 Earnings Call Highlights
2026-05-13 22:08:04
MDxHealth NASDAQ: MDXH reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company's focus on prostate cancer diagnostics.
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
2026-05-13 21:10:48
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Mdxhealth Reports Q1-2026 Results
2026-05-13 16:00:00
Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026. Michael K.
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
2026-04-30 16:00:00
Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended Mar
Frequently Asked Questions
-
What is the current MDxHealth S.A. (MDXH) stock price?
-
MDxHealth S.A.(NASDAQ:MDXH) stock price is $0.418 in the last trading session. During the trading session, MDXH stock reached the peak price of $5.33 while $0.4 was the lowest point it dropped to. The percentage change in MDXH stock occurred in the recent session was 1.95% while the dollar amount for the price change in MDXH stock was $0.01.
-
MDXH's industry and sector of operation?
-
The NASDAQ listed MDXH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of MDXH?
-
Kim Leroux | Executive Vice President of Revenue Cycle Management
Scott McMahan | Vice President of Finance and Accounting
Joseph Sollee | Executive Vice President of Corporate Development & General Counsel
Michael K. McGarrity | Chief Executive Officer & Executive Director
Ron Kalfus | Interim Chief Financial Officer -
How many employees does MDXH have?
-
Number of MDXH employees currently stands at 364. MDXH operates from CAP Business Center, Herstal, WA 4040, BE.
-
Link for MDXH official website?
-
Official Website of MDXH is: https://mdxhealth.com
-
How do I contact MDXH?
-
MDXH could be contacted at phone #32 4 257 70 21 and can also be accessed through its website. MDXH operates from CAP Business Center, Herstal, WA 4040, BE.
-
How many shares of MDXH are traded daily?
-
The average number of MDXH shares traded daily for last 3 months was 840.79K.
-
What is the market cap of MDXH currently?
-
The market value of MDXH currently stands at $21.47M with its latest stock price at $0.418